Movetis clinical trials

Acquired by Takeda, Jan 8, 2019 · source ↗

The registry lists 24 studies whose lead sponsor is Movetis. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 26, 2013.

Studies

Recruiting first, then most recently updated. Showing 24 of 24. All Takeda studies →

• Efficacy and Safety Study of Prucalopride to Treat Chronic ConstipationCompletedNCT00488137Phase 3

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Efficacy and Safety Study of Prucalopride for the Treatment of Patients With Chronic ConstipationCompletedNCT00485940Phase 3

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Efficacy and Safety Study of Prucalopride for the Treatment of Chronic ConstipationCompletedNCT00483886Phase 3

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Single Dose Pharmacokinetics of Prucalopride in Paediatric Subjects, With Functional Faecal RetentionCompletedNCT01674166Phase 1

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Prucalopride Subjects With Renal ImpairmentCompletedNCT01674192Phase 1

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Prucalopride in Paediatric Subjects, With Functional Faecal RetentionCompletedNCT01670669Phase 1

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic ImpairmentCompletedNCT01134185Phase 1

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• M0001 Effects on Oral Contraceptive Plasma LevelsCompletedNCT01036893Phase 1

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or NormonatraemiaCompletedNCT01179607Phase 2

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Study to Evaluate Long-Term Tolerability and Safety of Oral Prucalopride in Chronic ConstipationCompletedNCT01070615Phase 3

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic ConstipationCompletedNCT00987844Phase 3

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG ParametersCompletedNCT00903747Phase 1

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Safety Study of Prucalopride in Healthy VolunteersCompletedNCT00793429Phase 1

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)CompletedNCT00793247Phase 2

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Evaluation of the Safety and Tolerability of Prucalopride in Constipated Elderly Subjects Living in a Nursing FacilityCompletedNCT00627692Phase 2

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Efficacy and Safety Study of Prucalopride for the Treatment of Elderly Patients With Chronic ConstipationCompletedNCT00487422Phase 3

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic ConstipationCompletedNCT00596596Phase 2

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Efficacy and Safety Study of the Effect of Dose-Titration of Prucalopride for The Treatment of Chronic ConstipationCompletedNCT00577018Phase 3

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Efficacy and Safety Study of Prucalopride for the Treatment of Chronic ConstipationCompletedNCT00631813Phase 2

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Efficacy and Safety Study of Prucalopride for the Treatment of Chronic ConstipationCompletedNCT00617513Phase 2

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Efficacy and Safety Study of Prucalopride for the Re-Treatment of Chronic ConstipationCompletedNCT00598338Phase 3

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Prucalopride in Patients With Chronic Idiopathic ConstipationCompletedNCT00575614Phase 2

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• A Trial in Healthy Volunteers, to Evaluate the Tolerability and Cardiac Safety of PrucaloprideCompletedNCT00488215Phase 1

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda

• Effect of Prucalopride in Patients With Severe Chronic Idiopathic ConstipationCompletedNCT00576511Phase 2

  Sponsor listed in the registry: Movetis · First submitted before Movetis became part of Takeda